Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00734422

Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants

Sponsor: VU University of Amsterdam

Interventions Virtual Reality Exposure Therapy

Updated 6 times since 2017 Last updated: Sep 11, 2018 Started: Jul 31, 2008 Primary completion: Jun 30, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Phobic Disorders, this trial is completed. The trial is conducted by VU University of Amsterdam and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Oct 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

VU University of Amsterdam

Data source: VU University of Amsterdam

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands